Phase	B:C0920321
I	I:C0920321
Dose	O
-	O
Escalation	O
Study	O
of	O
Pilaralisib	O
(	O
SAR245408	O
,	O
XL147	O
)	O
in	O
Combination	O
with	I:C0281297
Paclitaxel	I:C0281297
and	I:C0281297
Carboplatin	I:C0281297
in	O
Patients	O
with	O
Solid	O
Tumors	I:C0280100
.	O

Phase	O
I	I:C0920321
Dose	O
-	O
Escalation	O
Study	B:C2603343
of	O
Pilaralisib	O
(	O
SAR245408	O
,	O
XL147	O
)	O
in	O
Combination	O
with	I:C0281297
Paclitaxel	I:C0281297
and	I:C0281297
Carboplatin	I:C0281297
in	O
Patients	O
with	O
Solid	O
Tumors	I:C0280100
.	O

Phase	O
I	I:C0920321
Dose	O
-	O
Escalation	O
Study	O
of	O
Pilaralisib	B:C1254351
(	O
SAR245408	O
,	O
XL147	O
)	O
in	O
Combination	O
with	I:C0281297
Paclitaxel	I:C0281297
and	I:C0281297
Carboplatin	I:C0281297
in	O
Patients	O
with	O
Solid	O
Tumors	I:C0280100
.	O

Phase	O
I	I:C0920321
Dose	O
-	O
Escalation	O
Study	O
of	O
Pilaralisib	O
(	O
SAR245408	B:C3657458
,	O
XL147	O
)	O
in	O
Combination	O
with	I:C0281297
Paclitaxel	I:C0281297
and	I:C0281297
Carboplatin	I:C0281297
in	O
Patients	O
with	O
Solid	O
Tumors	I:C0280100
.	O

Phase	O
I	I:C0920321
Dose	O
-	O
Escalation	O
Study	O
of	O
Pilaralisib	O
(	O
SAR245408	O
,	O
XL147	B:C2347424
)	O
in	O
Combination	O
with	I:C0281297
Paclitaxel	I:C0281297
and	I:C0281297
Carboplatin	I:C0281297
in	O
Patients	O
with	O
Solid	O
Tumors	I:C0280100
.	O

Phase	O
I	I:C0920321
Dose	O
-	O
Escalation	O
Study	O
of	O
Pilaralisib	O
(	O
SAR245408	O
,	O
XL147	O
)	O
in	O
Combination	B:C0281297
with	I:C0281297
Paclitaxel	I:C0281297
and	I:C0281297
Carboplatin	I:C0281297
in	O
Patients	O
with	O
Solid	O
Tumors	I:C0280100
.	O

Phase	O
I	I:C0920321
Dose	O
-	O
Escalation	O
Study	O
of	O
Pilaralisib	O
(	O
SAR245408	O
,	O
XL147	O
)	O
in	O
Combination	O
with	I:C0281297
Paclitaxel	I:C0281297
and	I:C0281297
Carboplatin	I:C0281297
in	O
Patients	O
with	O
Solid	B:C0280100
Tumors	I:C0280100
.	O

Despite	O
involvement	O
of	O
PI3K	O
pathway	O
activation	O
in	O
tumorigenesis	B:C0007621
of	O
solid	O
tumors	I:C0280100
,	O
single	O
-	O
agent	O
PI3K	O
inhibitors	I:C4041090
have	O
shown	O
modest	O
clinical	O
activity	I:C1516654
.	O

Despite	O
involvement	O
of	O
PI3K	O
pathway	O
activation	O
in	O
tumorigenesis	O
of	O
solid	B:C0280100
tumors	I:C0280100
,	O
single	O
-	O
agent	O
PI3K	O
inhibitors	I:C4041090
have	O
shown	O
modest	O
clinical	O
activity	I:C1516654
.	O

Despite	O
involvement	O
of	O
PI3K	O
pathway	O
activation	O
in	O
tumorigenesis	O
of	O
solid	O
tumors	I:C0280100
,	O
single	O
-	O
agent	O
PI3K	B:C4041090
inhibitors	I:C4041090
have	O
shown	O
modest	O
clinical	O
activity	I:C1516654
.	O

Despite	O
involvement	O
of	O
PI3K	O
pathway	O
activation	O
in	O
tumorigenesis	O
of	O
solid	O
tumors	I:C0280100
,	O
single	O
-	O
agent	O
PI3K	O
inhibitors	I:C4041090
have	O
shown	O
modest	O
clinical	B:C1516654
activity	I:C1516654
.	O

Preclinical	O
evidence	O
suggests	O
that	O
combining	O
PI3K	B:C4041090
pathway	I:C4041090
inhibitors	I:C4041090
and	O
chemotherapy	O
can	O
enhance	O
antitumor	O
effects	I:C0243095
.	O

Preclinical	O
evidence	O
suggests	O
that	O
combining	O
PI3K	O
pathway	I:C4041090
inhibitors	I:C4041090
and	O
chemotherapy	B:C3665472
can	O
enhance	O
antitumor	O
effects	I:C0243095
.	O

Preclinical	O
evidence	O
suggests	O
that	O
combining	O
PI3K	O
pathway	I:C4041090
inhibitors	I:C4041090
and	O
chemotherapy	O
can	O
enhance	O
antitumor	B:C0243095
effects	I:C0243095
.	O

In	O
patients	O
with	O
solid	B:C0280100
tumors	I:C0280100
,	O
the	O
PI3K	O
inhibitor	I:C4041090
pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
.	O

In	O
patients	O
with	O
solid	O
tumors	I:C0280100
,	O
the	O
PI3K	B:C4041090
inhibitor	I:C4041090
pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
.	O

In	O
patients	O
with	O
solid	O
tumors	I:C0280100
,	O
the	O
PI3K	O
inhibitor	I:C4041090
pilaralisib	B:C1254351
had	O
a	O
favorable	O
safety	O
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
.	O

In	O
patients	O
with	O
solid	O
tumors	I:C0280100
,	O
the	O
PI3K	O
inhibitor	I:C4041090
pilaralisib	O
had	O
a	O
favorable	O
safety	B:C1705187
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
.	O

In	O
patients	O
with	O
solid	O
tumors	I:C0280100
,	O
the	O
PI3K	O
inhibitor	I:C4041090
pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	B:C1979963
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
.	O

In	O
patients	O
with	O
solid	O
tumors	I:C0280100
,	O
the	O
PI3K	O
inhibitor	I:C4041090
pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	B:C0243095
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
.	O

In	O
patients	O
with	O
solid	O
tumors	I:C0280100
,	O
the	O
PI3K	O
inhibitor	I:C4041090
pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	B:C0281297
plus	I:C0281297
carboplatin	I:C0281297
.	O

Further	O
clinical	B:C4084924
evaluation	I:C4084924
is	O
warranted	O
to	O
identify	O
effective	O
combination	O
strategies	O
with	O
PI3K	O
pathway	I:C4041090
inhibitors	I:C4041090
.	O

Further	O
clinical	O
evaluation	I:C4084924
is	O
warranted	O
to	O
identify	O
effective	O
combination	B:C0013162
strategies	O
with	O
PI3K	O
pathway	I:C4041090
inhibitors	I:C4041090
.	O

Further	O
clinical	O
evaluation	I:C4084924
is	O
warranted	O
to	O
identify	O
effective	O
combination	O
strategies	O
with	O
PI3K	B:C4041090
pathway	I:C4041090
inhibitors	I:C4041090
.	O

Pilaralisib	B:C1254351
(	O
SAR245408	O
)	O
is	O
an	O
oral	O
,	O
pan-class	O
I	I:C0441885
phosphoinositide	O
3	I:C4041090
-	I:C4041090
kinase	I:C4041090
(	I:C4041090
PI3K	I:C4041090
)	I:C4041090
inhibitor	I:C4041090
.	O

Pilaralisib	O
(	O
SAR245408	B:C3657458
)	O
is	O
an	O
oral	O
,	O
pan-class	O
I	I:C0441885
phosphoinositide	O
3	I:C4041090
-	I:C4041090
kinase	I:C4041090
(	I:C4041090
PI3K	I:C4041090
)	I:C4041090
inhibitor	I:C4041090
.	O

Pilaralisib	O
(	O
SAR245408	O
)	O
is	O
an	O
oral	B:C1272919
,	O
pan-class	O
I	I:C0441885
phosphoinositide	O
3	I:C4041090
-	I:C4041090
kinase	I:C4041090
(	I:C4041090
PI3K	I:C4041090
)	I:C4041090
inhibitor	I:C4041090
.	O

Pilaralisib	O
(	O
SAR245408	O
)	O
is	O
an	O
oral	O
,	O
pan-class	B:C0441885
I	I:C0441885
phosphoinositide	O
3	I:C4041090
-	I:C4041090
kinase	I:C4041090
(	I:C4041090
PI3K	I:C4041090
)	I:C4041090
inhibitor	I:C4041090
.	O

Pilaralisib	O
(	O
SAR245408	O
)	O
is	O
an	O
oral	O
,	O
pan-class	O
I	I:C0441885
phosphoinositide	B:C4041090
3	I:C4041090
-	I:C4041090
kinase	I:C4041090
(	I:C4041090
PI3K	I:C4041090
)	I:C4041090
inhibitor	I:C4041090
.	O

This	O
phase	B:C0920321
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	B:C2603343
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	B:C0220825
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	B:C1705187
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	B:C0031327
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	B:C0031327
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	B:C0851347
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	B:C1254351
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	B:C0006935
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	B:C0039225
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	B:C0013058
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	B:C0281297
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	O
tumors	I:C0280100
.	O

This	O
phase	O
I	I:C0920321
dose	O
-	O
escalation	O
study	O
evaluated	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
safety	O
,	O
pharmacokinetics	O
(	O
pharmacokinetics	O
)	O
,	O
and	O
pharmacodynamics	O
of	O
pilaralisib	O
in	O
capsule	O
and	O
tablet	O
formulations	O
,	O
administered	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
in	O
patients	O
with	O
advanced	O
solid	B:C0280100
tumors	I:C0280100
.	O

Pilaralisib	B:C1254351
was	O
administered	O
once	O
daily	O
(	O
QD	O
)	O
;	O
paclitaxel	O
(	O
up	O
to	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	O
(	O
up	O
to	O
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
of	O
6	O
)	O
were	O
administered	O
on	O
day	O
1	O
of	O
21	O
-	O
day	O
cycles	O
.	O

Pilaralisib	O
was	O
administered	O
once	O
daily	O
(	O
QD	O
)	O
;	O
paclitaxel	B:C0144576
(	O
up	O
to	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	O
(	O
up	O
to	O
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
of	O
6	O
)	O
were	O
administered	O
on	O
day	O
1	O
of	O
21	O
-	O
day	O
cycles	O
.	O

Pilaralisib	O
was	O
administered	O
once	O
daily	O
(	O
QD	O
)	O
;	O
paclitaxel	O
(	O
up	O
to	O
175	O
mg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
carboplatin	B:C0079083
(	O
up	O
to	O
area	O
under	O
the	O
curve	O
[	O
AUC	O
]	O
of	O
6	O
)	O
were	O
administered	O
on	O
day	O
1	O
of	O
21	O
-	O
day	O
cycles	O
.	O

An	O
MTD	O
expansion	O
cohort	B:C0599755
of	O
patients	O
with	O
endometrial	O
carcinoma	I:C0476089
was	O
included	O
.	O

An	O
MTD	O
expansion	O
cohort	O
of	O
patients	O
with	O
endometrial	B:C0476089
carcinoma	I:C0476089
was	O
included	O
.	O

Six	O
patients	O
(	O
10.3	O
%	O
)	O
had	O
dose	O
-	O
limiting	O
toxicities	B:C0013221
,	O
of	O
which	O
only	O
rash	O
(	O
two	O
patients	O
,	O
3.4	O
%	O
)	O
occurred	O
in	O
more	O
than	O
one	O
patient	O
.	O

Six	O
patients	O
(	O
10.3	O
%	O
)	O
had	O
dose	O
-	O
limiting	O
toxicities	O
,	O
of	O
which	O
only	O
rash	B:C0015230
(	O
two	O
patients	O
,	O
3.4	O
%	O
)	O
occurred	O
in	O
more	O
than	O
one	O
patient	O
.	O

The	O
MTD	O
of	O
pilaralisib	B:C1254351
tablets	O
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
was	O
determined	O
to	O
be	O
200	O
mg	O
QD	O
.	O

The	O
MTD	O
of	O
pilaralisib	O
tablets	B:C0039225
in	O
combination	O
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
was	O
determined	O
to	O
be	O
200	O
mg	O
QD	O
.	O

The	O
MTD	O
of	O
pilaralisib	O
tablets	O
in	O
combination	B:C0281297
with	I:C0281297
paclitaxel	I:C0281297
and	I:C0281297
carboplatin	I:C0281297
was	O
determined	O
to	O
be	O
200	O
mg	O
QD	O
.	O

The	O
most	O
frequently	O
reported	B:C0700287
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
of	O
any	O
grade	O
were	O
neutropenia	O
(	O
67.2	O
%	O
)	O
and	O
thrombocytopenia	O
(	O
67.2	O
%	O
)	O
.	O

The	O
most	O
frequently	O
reported	O
adverse	B:C0877248
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
of	O
any	O
grade	O
were	O
neutropenia	O
(	O
67.2	O
%	O
)	O
and	O
thrombocytopenia	O
(	O
67.2	O
%	O
)	O
.	O

The	O
most	O
frequently	O
reported	O
adverse	O
events	I:C0877248
(	O
adverse	B:C0877248
events	I:C0877248
)	O
of	O
any	O
grade	O
were	O
neutropenia	O
(	O
67.2	O
%	O
)	O
and	O
thrombocytopenia	O
(	O
67.2	O
%	O
)	O
.	O

The	O
most	O
frequently	O
reported	O
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
of	O
any	O
grade	B:C0441800
were	O
neutropenia	O
(	O
67.2	O
%	O
)	O
and	O
thrombocytopenia	O
(	O
67.2	O
%	O
)	O
.	O

The	O
most	O
frequently	O
reported	O
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
of	O
any	O
grade	O
were	O
neutropenia	B:C0027947
(	O
67.2	O
%	O
)	O
and	O
thrombocytopenia	O
(	O
67.2	O
%	O
)	O
.	O

The	O
most	O
frequently	O
reported	O
adverse	O
events	I:C0877248
(	O
adverse	O
events	I:C0877248
)	O
of	O
any	O
grade	O
were	O
neutropenia	O
(	O
67.2	O
%	O
)	O
and	O
thrombocytopenia	B:C0040034
(	O
67.2	O
%	O
)	O
.	O

pharmacokinetics	B:C0031327
data	O
showed	O
no	O
interaction	O
between	O
pilaralisib	O
and	O
paclitaxel	O
/	I:C0281297
carboplatin	I:C0281297
.	O

pharmacokinetics	O
data	O
showed	O
no	B:C1513916
interaction	O
between	O
pilaralisib	O
and	O
paclitaxel	O
/	I:C0281297
carboplatin	I:C0281297
.	O

pharmacokinetics	O
data	O
showed	O
no	O
interaction	B:C0687133
between	O
pilaralisib	O
and	O
paclitaxel	O
/	I:C0281297
carboplatin	I:C0281297
.	O

pharmacokinetics	O
data	O
showed	O
no	O
interaction	O
between	O
pilaralisib	B:C1254351
and	O
paclitaxel	O
/	I:C0281297
carboplatin	I:C0281297
.	O

pharmacokinetics	O
data	O
showed	O
no	O
interaction	O
between	O
pilaralisib	O
and	O
paclitaxel	B:C0281297
/	I:C0281297
carboplatin	I:C0281297
.	O

Tumor	B:C0475358
tissue	I:C0475358
showed	O
moderate	O
inhibition	O
of	O
PI3K	O
and	O
mitogen	O
-	I:C1518102
activated	I:C1518102
protein	I:C1518102
kinase	I:C1518102
(	I:C1518102
MAPK	I:C1518102
)	I:C1518102
pathways	I:C1518102
.	O

Tumor	O
tissue	I:C0475358
showed	O
moderate	O
inhibition	B:C0021469
of	O
PI3K	O
and	O
mitogen	O
-	I:C1518102
activated	I:C1518102
protein	I:C1518102
kinase	I:C1518102
(	I:C1518102
MAPK	I:C1518102
)	I:C1518102
pathways	I:C1518102
.	O

Tumor	O
tissue	I:C0475358
showed	O
moderate	O
inhibition	O
of	O
PI3K	O
and	O
mitogen	B:C1518102
-	I:C1518102
activated	I:C1518102
protein	I:C1518102
kinase	I:C1518102
(	I:C1518102
MAPK	I:C1518102
)	I:C1518102
pathways	I:C1518102
.	O

Seven	O
of	O
52	O
evaluable	O
patients	O
had	O
a	O
partial	B:C1521726
response	I:C1521726
(	O
partial	O
response	I:C1521726
;	O
13.5	O
%	O
)	O
.	O

Seven	O
of	O
52	O
evaluable	O
patients	O
had	O
a	O
partial	O
response	I:C1521726
(	O
partial	B:C1521726
response	I:C1521726
;	O
13.5	O
%	O
)	O
.	O

Pilaralisib	B:C1254351
had	O
a	O
favorable	O
safety	O
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
in	O
solid	O
tumors	I:C0280100
.	O

Pilaralisib	O
had	O
a	O
favorable	O
safety	B:C1705187
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
in	O
solid	O
tumors	I:C0280100
.	O

Pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	B:C1979963
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
in	O
solid	O
tumors	I:C0280100
.	O

Pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	B:C0243095
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
in	O
solid	O
tumors	I:C0280100
.	O

Pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	B:C0281297
plus	I:C0281297
carboplatin	I:C0281297
in	O
solid	O
tumors	I:C0280100
.	O

Pilaralisib	O
had	O
a	O
favorable	O
safety	O
profile	O
but	O
did	O
not	O
enhance	O
the	O
antitumor	O
activity	I:C0243095
of	O
paclitaxel	O
plus	I:C0281297
carboplatin	I:C0281297
in	O
solid	B:C0280100
tumors	I:C0280100
.	O

